focus -WSS

focus

author：leisure time 2025-10-01 21:40:16 - browse：8235

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： FDA warns J&J's Abiomed: We will regulate your software

explore

WSS

A solution to the after

New documents shed light on MD Anderson Cancer Institute feud

STAT Summit: GSK CEO on pharma giant's new direction

The explosion of genetic testing requires a new approach

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Ed Silverman on new gene therapies, biosimilars, coffee, and more

knowledge

focus

entertainment

Sports medicine is finally prioritizing gender equality

The Harvard botanist who searched for psychedelics in the Amazon

Virginia high school admissions case could be legal follow

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

23andMe had bad news about my health. I wish a person had delivered it

Hospital price transparency does save money, advocate argues

ChatGPT in medicine: STAT answers readers' burning questions

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Hepatitis C has a cure — but many Americans still lack access to it

Dario to buy mental health app maker Twill in cash and stock deal

leisure time

Will Ozempic

UnitedHealth’s board chair also owns a personal investment firm

Solve the antibiotic resistance crisis with preventive drugs

R1 RCM gets $5.8 billion buyout offer from private equity firm

STAT Readout Newsletter: Today's biggest biotech updates

Antivenom research: Lessons from HIV applied in search for universal antidote

entertainment

focus

explore

hotspot